ImmunoGen Inc. [NASDAQ: IMGN] stock went on an upward path that rose over 5.07% on Thursday, amounting to a one-week price decrease of less than -4.60%. The company report on September 2, 2020 that ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference.
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will present at the upcoming H.C. Wainwright Virtual Global Investment Conference. The presentation is scheduled for September 14, 2020 at 11am ET.
A webcast of the presentation will be accessible through the Investors and Media section of the Company’s website on www.immunogen.com. Following the live webcast, a replay will be available at the same location.
Over the last 12 months, IMGN stock rose by 15.48%. The average equity rating for IMGN stock is currently 2.20, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $657.52 million, with 174.35 million shares outstanding and 173.49 million shares in the current float. Compared to the average trading volume of 2.16M shares, IMGN stock reached a trading volume of 2382816 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on ImmunoGen Inc. [IMGN]:
H.C. Wainwright have made an estimate for ImmunoGen Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 17, 2019. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $4 to $5. The new note on the price target was released on August 13, 2019, representing the official price target for ImmunoGen Inc. stock.
The Average True Range (ATR) for ImmunoGen Inc. is set at 0.21, with the Price to Sales ratio for IMGN stock in the period of the last 12 months amounting to 7.60.
IMGN Stock Performance Analysis:
ImmunoGen Inc. [IMGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.60. With this latest performance, IMGN shares dropped by -3.12% in over the last four-week period, additionally plugging by 29.07% over the last 6 months – not to mention a rise of 15.48% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IMGN stock in for the last two-week period is set at 48.12, with the RSI for the last a single of trading hit 51.14, and the three-weeks RSI is set at 46.16 for ImmunoGen Inc. [IMGN]. The present Moving Average for the last 50 days of trading for this stock 4.09, while it was recorded at 3.56 for the last single week of trading, and 4.26 for the last 200 days.
Insight into ImmunoGen Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and ImmunoGen Inc. [IMGN] shares currently have an operating margin of -85.98. ImmunoGen Inc.’s Net Margin is presently recorded at -126.57.
Return on Total Capital for IMGN is now -60.07, given the latest momentum, and Return on Invested Capital for the company is -125.91. Additionally, IMGN Total Debt to Total Capital is recorded at 202.50, with Total Debt to Total Assets ending up at 63.92.
Reflecting on the efficiency of the workforce at the company, ImmunoGen Inc. [IMGN] managed to generate an average of -$1,388,440 per employee. Receivables Turnover for the company is 4.19 with a Total Asset Turnover recorded at a value of 0.31.ImmunoGen Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 2.70.
IMGN Stock EPS
With the latest financial reports released by the company, ImmunoGen Inc. posted -0.15/share EPS, while the average EPS was predicted by analysts to be reported at -0.18/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 16.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IMGN.
ImmunoGen Inc. [IMGN] Insider Position Details
There are presently around $518 million, or 80.10% of IMGN stock, in the hands of institutional investors. The top three institutional holders of IMGN stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 23,311,638, which is approximately 21.723% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 14,904,994 shares of the stock with an approximate value of $55.6 million in IMGN stocks shares; and BLACKROCK INC., currently with $53.87 million in IMGN stock with ownership of nearly 6.03% of the company’s market capitalization.
Positions in ImmunoGen Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 96 institutional holders increased their position in ImmunoGen Inc. [NASDAQ:IMGN] by around 19,345,749 shares. Additionally, 82 investors decreased positions by around 18,296,424 shares, while 39 investors held positions by with 101,328,816 shares. The mentioned changes placed institutional holdings at 138,970,989 shares, according to the latest SEC report filing. IMGN stock had 29 new institutional investments in for a total of 2,349,948 shares, while 29 institutional investors sold positions of 7,750,442 shares during the same period.